Jane Street’s Pyxis Oncology PYXS Stock Holding History

Jane Street’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.2K	Buy	+25,500	New	+$38.4K	﹤0.01%	11066

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street's PYXS Position: Q1 2026 in Review

Jane Street reduced its Pyxis Oncology (PYXS) stake by 61% in Q1 2026, selling an estimated $726K and leaving 304,459 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #8341.

Jane Street first reported a position in PYXS in Q1 2023 and has held it in 10 quarters since. The position peaked at $904K in Q4 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

Jane Street held 304,459 shares of Pyxis Oncology worth $445K as of Q1 2026.
Jane Street sold 481,551 Pyxis Oncology shares in Q1 2026, an estimated $726K.
Pyxis Oncology made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8341 holding.
Jane Street first reported a position in Pyxis Oncology in Q1 2023 and has held it in 10 quarters since.
Jane Street's Pyxis Oncology position peaked at $904K in Q4 2025.
78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.